HVE Stock Overview
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innoviva, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.40 |
| 52 Week High | US$18.60 |
| 52 Week Low | US$12.20 |
| Beta | 0.57 |
| 11 Month Change | -1.14% |
| 3 Month Change | -0.57% |
| 1 Year Change | 38.10% |
| 33 Year Change | 15.23% |
| 5 Year Change | 58.18% |
| Change since IPO | 75.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| HVE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -1.7% | -1.8% |
| 1Y | 38.1% | -12.7% | 13.2% |
Return vs Industry: HVE exceeded the German Pharmaceuticals industry which returned -12.7% over the past year.
Return vs Market: HVE exceeded the German Market which returned 13.2% over the past year.
Price Volatility
| HVE volatility | |
|---|---|
| HVE Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HVE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HVE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 112 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. Fundamentals Summary
| HVE fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | €134.20m |
| Revenue (TTM) | €304.98m |
8.3x
P/E Ratio3.6x
P/S RatioIs HVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVE income statement (TTM) | |
|---|---|
| Revenue | US$330.50m |
| Cost of Revenue | US$31.82m |
| Gross Profit | US$298.68m |
| Other Expenses | US$153.25m |
| Earnings | US$145.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.32 |
| Gross Margin | 90.37% |
| Net Profit Margin | 44.00% |
| Debt/Equity Ratio | 77.8% |
How did HVE perform over the long term?
See historical performance and comparison